

Attorney Docket No.: DEX-0087  
Inventors: Recipon et al.  
Serial No.: 09/705,500  
Filing Date: November 3, 2000  
Page 2

This listing of the claims will replace all prior versions and listings of claims in the application:

Listing of the claims:

Claim 1 (currently amended): A method for diagnosing the presence of cancer in a patient comprising:

(a) determining levels of Lng108 in cells, tissues or bodily fluids in a patient; and

(b) comparing the determined levels of Lng108 with levels of Lng108 in cells, tissues or bodily fluids from a normal human control, wherein ~~a change~~ an increase in determined levels of Lng108 in said patient versus normal human control is associated with the presence of cancer and wherein Lng108 comprises a polynucleotide of SEQ ID NO:1 or 2, a polynucleotide which ~~hybridizes under stringent conditions to an antisense sequence of SEQ ID NO:1 or 2, due to degeneracy in genetic coding, comprise variations in nucleotide sequence as compared to SEQ ID NO: 1 or 2, but which still encode the same protein,~~ or a protein expressed by a polynucleotide sequence of SEQ ID NO:1 or 2.

Claim 2 (currently amended): A method of diagnosing metastases of cancer in a patient comprising:

(a) identifying a patient having cancer ~~that is not known to have metastasized;~~

Attorney Docket No.: DEX-0087  
Inventors: Recipon et al.  
Serial No.: 09/705,500  
Filing Date: November 3, 2000  
Page 3

(b) determining Lng108 levels in a sample of cells, tissues, or bodily fluid from said patient; and

(c) comparing the determined Lng108 levels with levels of Lng108 in cells, tissue, or bodily fluid of a normal human control, wherein an increase in determined Lng108 levels in the patient versus the normal human control is associated with a cancer which has metastasized and wherein Lng108 comprises a polynucleotide of SEQ ID NO:1 or 2, a polynucleotide which ~~hybridizes under stringent conditions to an antisense sequence of SEQ ID NO:1 or 2, due to degeneracy in genetic coding, comprise variations in nucleotide sequence as compared to SEQ ID NO: 1 or 2, but which still encode the same protein~~, or a protein expressed by a polynucleotide sequence of SEQ ID NO:1 or 2.

Claim 3 (currently amended): A method of staging cancer in a patient having cancer comprising:

- (a) identifying a patient having cancer;
- (b) determining Lng108 levels in a sample of cells, tissue, or bodily fluid from said patient; and
- (c) comparing determined Lng108 levels with levels of Lng108 in cells, tissues, or bodily fluid of a normal human control, wherein an increase in determined Lng108 levels in said patient versus the normal human control is associated with a cancer which

Attorney Docket No.: DEX-0087  
Inventors: Recipon et al.  
Serial No.: 09/705,500  
Filing Date: November 3, 2000  
Page 4

is progressing and a decrease in the determined Lng108 levels is associated with a cancer which is regressing or in remission and wherein Lng108 comprises a polynucleotide of SEQ ID NO:1 or 2, a polynucleotide which ~~hybridizes under stringent conditions to an antisense sequence of SEQ ID NO:1 or 2, due to degeneracy in genetic coding, comprise variations in nucleotide sequence as compared to SEQ ID NO: 1 or 2, but which still encode the same protein~~, or a protein expressed by a polynucleotide sequence of SEQ ID NO:1 or 2.

Claim 4 (currently amended): A method of monitoring cancer in a patient for the onset of metastasis comprising:

(a) identifying a patient having cancer that is not known to have metastasized;

(b) periodically determining levels of Lng108 in samples of cells, tissues, or bodily fluid from said patient; and

(c) comparing the periodically determined Lng108 levels with levels of Lng108 in cells, tissues, or bodily fluid of a normal human control, wherein an increase in any one of the periodically determined Lng108 levels in the patient versus the normal human control is associated with a cancer which has metastasized and wherein Lng108 comprises a polynucleotide of SEQ ID NO:1 or 2, a polynucleotide which ~~hybridizes under stringent conditions to an~~

Attorney Docket No.: DEX-0087  
Inventors: Recipon et al.  
Serial No.: 09/705,500  
Filing Date: November 3, 2000  
Page 5

~~antisense sequence of SEQ ID NO: 1 or 2, due to degeneracy in genetic coding, comprise variations in nucleotide sequence as compared to SEQ ID NO: 1 or 2, but which still encode the same protein, or a protein expressed by a polynucleotide sequence of SEQ ID NO: 1 or 2.~~

Claim 5 (currently amended): A method of monitoring a change in stage of cancer in a patient comprising:

- (a) identifying a patient having cancer;
- (b) periodically determining levels of Lng108 in cells, tissues, or bodily fluid from said patient; and
- (c) comparing the periodically determined Lng108 levels with levels of Lng108 in cells, tissues, or bodily fluid of a normal human control, wherein an increase in any one of the periodically determined Lng108 levels in the patient versus the normal human control is associated with a cancer which is progressing in stage and a decrease is associated with a cancer which is regressing in stage or in remission and wherein Lng108 comprises a polynucleotide of SEQ ID NO: 1 or 2, a polynucleotide which ~~hybridizes under stringent conditions to an antisense sequence of SEQ ID NO: 1 or 2, due to degeneracy in genetic coding, comprise variations in nucleotide sequence as compared to SEQ ID NO: 1 or 2, but which still encode the same protein, or a protein~~

Attorney Docket No.: DEX-0087  
Inventors: Recipon et al.  
Serial No.: 09/705,500  
Filing Date: November 3, 2000  
Page 6

expressed by a polynucleotide sequence of SEQ ID NO:1 or 2.

Claims 6-11 (canceled)

Claim 12 (previously amended): The method of claim 1, 2, 3,  
4 or 5 wherein the cancer is lung cancer.

Claims 13-14 (canceled)

---